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Purpose: This study compares the effect of topical diclofenac with that of betamethasone 
against postoperative increase of intraocular pressure (IOP) after cataract surgery in 
normal patients, and also investigated the risk factors for postoperative increase of IOP in 
each group.
Methods: Fifty consecutive patients without systemic disease who have bilateral and 
symmetrical cataracts underwent uncomplicated cataract surgery in both eyes (100 eyes in 
total). Postoperatively, topical diclofenac was applied 4 times daily to one eye, and topical 
betamethasone to the other eye in each patient. IOP and best corrected logMAR visual 
acuity (BCVA) in each eye were measured up to 8 weeks. Total surgery time and effective 
phacoemulsiﬁ  cation time (EPT) for each case was recorded.
Results: BCVA in both diclofenac- and betamethasone-treated eyes signiﬁ  cantly improved 
after the cataract surgery; however, no statistical difference in VA was noted between the 
diclofenac- and betamethasone-treated eyes throughout the observation period. IOP in the 
diclofenac-treated eyes decreased with time, in contrast to the IOP in the betamethasone-treated 
eyes, which showed a slight increase. At 4 and 8 weeks postoperatively, there was signiﬁ  cant 
difference between these two eye groups. Multiple regression analysis revealed that postoperative 
increase in IOP at 8 weeks in the betamethasone-treated eyes was closely correlated with total 
surgery time and EPT, but the IOP in the diclofenac-treated eyes showed no correlation with 
any surgical or clinical parameters.
Conclusions: Postoperative increase in IOP after cataract surgery was affected by total surgery 
time and EPT in the betamethasone-treated eye. The time for surgery and EPT is longer in 
complicated cases including patients with a hard nucleus or small pupils, and also longer for 
beginning surgeons and in older patients. In these cases, diclofenac in place of betamethasone as 
a postoperative topical antiinﬂ  ammatory drug is recommended for the prevention of postoperative 
increase in IOP.
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Modern cataract surgery uses a small incision and a shorter operation time; therefore, 
postoperative inﬂ  ammation is rarely seen. Nevertheless, cataract surgery for severe 
cases, including cataract grade greater than Emery classiﬁ  cation level IV, sometimes 
takes longer time for emulsiﬁ  cation, and causes post-operative inﬂ  ammation and a 
subsequent increase in intraocular pressure (IOP), which causes possible neuronal 
damage. Thus, to reduce the risk of inﬂ  ammation after cataract surgery, a topical 
antiinﬂ  ammatory drug application is widely used.1,2 Two classes of compounds 
are available: corticosteroids and nonsteroidal antiinﬂ  ammatory drugs (NSAIDs). 
Although both drugs are effective in suppressing postoperative inflammation, 
corticosteroids have been reported to increase IOP.3,4 Diclofenac is a NSAID which Clinical Ophthalmology 2009:3 96
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inhibits prostaglandin synthesis,5 and previous studies have 
assessed the effectiveness of diclofenac in treating ocular 
inﬂ  ammation.6–8 Although it has been reported that diclofenac 
does not cause postoperative increase of IOP,9 case-control 
studies have not been perfomed. A case-control study should 
be conducted in patients with eligible eyes, where one eye 
was treated with betamethasone and the other eye with 
diclofenac. These cases should be conducted in patients 
without systemic conditions.
In this paper, a prospective case-control compared and 
evaluated eyes treated with topical corticosteroids and those 
treated with topical NSAIDs for postoperative increase in 
IOP after cataract surgery. Also, the relationship between 
postoperative IOP and clinical factors, including age, 
gender, preoperative IOP, total surgery time, sonication 
time, and sonication power was investigated using multiple 
regression analysis. The ﬁ  nal goal of this study was to 
determine which cases are at risk for postoperative increase 
in IOP and should be treated with topical administration 
of NSAIDs.
Methods
Patient eligibility
In this prospective study, patients had uncomplicated senile 
cataracts in both eyes from grade III to IV based on Emery’s 
classiﬁ  cation.10 Exclusion criteria were ocular hypertension 
(IOP   21 mmHg), glaucoma requiring ocular medica-
tion, pseudoexfoliation, uveitis, an endothelial cell count 
less than 1500 cells/mm2, corneal opacity, high myopia, 
previous ocular surgery, systemic disease affecting the 
inﬂ  ammatory response such as diabetes mellitus, collagen 
disease requiring long-term systemic steroids or antiinﬂ  am-
matory drugs, and severe hypertension. Patients whose 
cataract grades were not symmetrical in both eyes were 
also excluded in this study. Intraoperative exclusion criteria 
were iatrogenic iris damage, retained cortical matter, and 
a serious complication such as posterior capsule rupture. 
50 consecutive patients (21 male; 29 female) participated 
in this study.
All patients received a comprehensive ocular examination 
before treatment and were followed for periodic examinations 
after the treatments. After informing the patient of the purpose 
of this study and the possible outcomes, informed consent 
was obtained from all patients prior to the intervention. 
This study was also approved by the Ethics Committee for 
Clinical Research at NTT East Japan Tohoku Hospital using 
procedures which conformed to the tenets of the Declaration 
of Helsinki.
Study design
All patients had cataract surgery performed in both eyes 
within a 1 week interval. Before cataract surgery, a topical 
antimicrobial drug, gatiﬂ  oxacin hydrate 0.3% ophthalmic 
solution (Gatiﬂ  o®; Senju Pharmaceutical Co. Ltd., Osaka, 
Japan), was administered 4 times/day in both eyes of 
each patient. The surgical technique used in this study 
consisted of a continuous curvilinear capsulorrhexis (CCC), 
phacoemulsiﬁ  cation, and implantation of a foldable acrylic 
IOL (Acryfold® YA-65BB; HOYA medicals, Tokyo, Japan) 
into the lens capsule through a 3.0 mm corneoscleral 
incision. Phacoemulsiﬁ  cation was done with an Alcon 
Legacy 20000TM unit with standard cassettes and tubing. 
The incision was not sutured. In each patient, cataract 
surgery in the eye with the worst visual acuity was done 
ﬁ  rst, then surgery in the other eye was completed within 
a week. If the visual acuity in both eyes was the same, 
then the right eye was chosen ﬁ  rst. The effect of 0.1% 
diclofenac (Diclod®; Wakamoto Pharmaceutical Co. Ltd., 
Tokyo, Japan), which is a phenylacetic acid derivative, on 
IOP after cataract surgery was compared to that of 0.1% 
betamethasone sodium phosphate (Rindelon®, Shionogi Co. 
Ltd., Osaka, Japan), which is a topical corticosteroid.
After the next-day examination (deﬁ  ned as day 1), topi-
cal administration of an antiinﬂ  ammatory drug was started; 
0.1% diclofenac and 0.3% gatiﬂ  oxacin were topically applied 
4 times/day to the left eye, and 0.1% betamethasone and 
0.3% gatiﬂ  oxacin were topically applied 4 times/day to 
the right eye. Drug applications were continued for at least 
8 weeks after the surgery.
Total surgery time (minutes) was recorded in each 
case. The sonication time (seconds) and mean phaco power 
(percentage) were also noted from the phaco unit’s display. 
The sonication time was deﬁ  ned as the time the foot pedal 
remained in position 3. The mean phaco power was deﬁ  ned 
as the power used during sonication time. The effective phaco 
time (EPT) was calculated using the following formula: 
EPT = sonication time X mean phaco power/100.
IOP and best corrected logMAR visual acuity (BCVA) in 
each eye were measured preoperatively and postoperatively 
at 3 and 7 days, and at 4 and 8 weeks after cataract surgery. 
The IOP data were obtained using pneumotonometry.
Statistical analysis
The data are presented as mean ± standard deviation. 
Statistical differences between follow-up points of the clinical 
course in the same eyes were assessed using the Wilcoxon 
signed-rank test, and the differences between the right and Clinical Ophthalmology 2009:3 97
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left eyes were assessed using the Mann Whitney U test 
(SPSS ver. 11; SPSS Inc., Chicago, IL, USA).
To clarify the change in IOP, delta IOP (∆IOP), deﬁ  ned as 
a subtraction in IOP at 8 weeks postoperatively from IOP at the 
preoperative exam, was calculated in each eye. To investigate 
the correlation between ∆IOP and clinical parameters, Pearson’s 
correlation coefﬁ  cient (r), and a p value were calculated. Since 
the number of samples was 50, a |r| value of more than 0.3 was 
considered a statistically signiﬁ  cant correlation. In all cases, 
p   0.05 was considered to be signiﬁ  cant.
To clarify which parameters contribute to ∆IOP, multiple 
regression analysis was performed. From multiple regression 
analysis, a standard partial regression coefﬁ  cient (b) and a 
p value in each clinical factor were calculated. Each amount 
of |b| value reﬂ  ects a degree of contribution for each factor 
to the prognosis. To conﬁ  rm the “goodness-of-ﬁ  t” in each 
multiple regression equation, analysis of variance (ANOVA) 
was performed and a p value of less than 0.05 was considered 
a good ﬁ  t.
Results
The ages of the patients ranged from 60 to 83 years with 
a mean of 74.8 ± 5.4 years. Twenty seven of 50 patients 
underwent cataract surgery in the right eye ﬁ  rst, and then 1 
week later in the other eye, while the remaining 23 patients 
underwent cataract surgery ﬁ  rst in the left eye and then in 
the right eye. The surgery was performed by a single surgeon 
(MS) and took less than 15 minutes, and no complications 
occurred.
Alteration of BCVA before and after 
the cataract surgery
Before cataract surgery, BCVA in the betamethasone-treated 
(right) eye was logMAR 0.348 ± 0.222, and BCVA in the 
diclofenac-treated (left) eye was logMAR 0.363 ± 0.233, 
thus showing no statistically signiﬁ  cant difference in BCVA 
(   p = 0.785). After the surgery, BCVA in all eyes improved, 
and at the ﬁ  nal period of 8 weeks after surgery, BCVA in the 
right eye was logMAR −0.026 ± 0.056, and in the left eye 
logMAR −0.028 ± 0.057, so that no statistically signiﬁ  cant 
difference existed between the two groups of eyes 1.992).
Change in IOP after topical 
administration of antiinﬂ  ammatory drugs
Before cataract surgery, IOP in the betamethasone-treated (right) 
eye was 14.9 ± 3.2 mmHg, and IOP in the diclofenac-treated 
(left) eye was 15.0 ± 3.2 mmHg, thus showing no statistically 
signiﬁ  cant difference between these two groups (   p = 0.986). 
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Figure 1 Clinical course in IOP after the cataract surgery in eyes with postoperative topical administration of betamethasone (closed circle) and that of diclofenac (open circle). 
The vertical bar indicates standard deviation of the mean. After 4 postoperative weeks, IOP in the betamethasone-treated eye showed a signiﬁ  cant increase with compared 
to that in diclofenac-treated eye.   The asterisk (*) indicates statistical signiﬁ  cance (p   0.05).Clinical Ophthalmology 2009:3 98
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As shown in Figure 1, IOP in the betamethasone-treated 
eyes gradually increased to 16.7 ±  4.3 mmHg (  p = 0.001). 
In contrast, IOP in the diclofenac-treated eyes gradually 
decreased to 14.0 ± 3.2 mmHg (    p   =  0.01). There was a 
statistically signiﬁ  cant difference in IOP between each of these 
groups at 4 (  p   0.001) and 8 weeks (  p   0.001).
Relationship between ∆IOP and total 
surgery time
The total surgery time was 8.58 ± 1.28 min in the 
betamethasone-treated (right) eyes, and 8.74 ± 1.29 min in 
the diclofenac-treated (left) eyes, which shows no statistically 
signiﬁ  cant difference between either group of eyes (p = 0.472). 
To investigate the correlation between ∆IOP and total surgery 
time, Pearson’s correlation coefﬁ  cient was calculated from 
each plot (Figure 2). ∆IOP in the betamethasone-treated eyes 
was closely correlated with the total surgery time (Figure 2A; 
r = 0.499, p = 0.002); in contrast, ∆IOP in the diclofenac-
treated eyes showed no correlation with the total surgery time 
(Figure 2B; r = 0.044, p = 0.763).
Relationship between ∆IOP and EPT
The EPT was 52.7 ± 16.6 sec in the betamethasone-treated 
(right) eyes, and 53.5 ± 14.9 sec in the diclofenac-treated 
(left) eyes, which shows no statistically signiﬁ  cant difference 
between both groups of eyes (  p = 0.206). To investigate the 
correlation between ∆IOP and the EPT, Pearson’s correlation 
coefﬁ  cient was calculated from each plot (Figure 3). ∆IOP in 
the betamethasone-treated eyes was closely correlated with 
the EPT (r = 0.535, p   0.001); in contrast, the ∆IOP in the 
diclofenac-treated eyes showed no correlation with the EPT 
(r = −0.080, p = 0.584).
Contribution of clinical factors to ∆IOP 
after cataract surgery
To investigate which clinical factors contributed to the ∆IOP, 
multiple regression analysis was performed. The clinical 
factors were age, gender, preoperative IOP, preoperative 
BCVA, total surgery time, and EPT. In the betamethasone-
treated (right) eyes, ∆IOP was +1.74 ± 3.41 mmHg, and 
the standard partial regression |b| of total surgery time 
(  p = 0.019) and EPT (  p = 0.002) was signiﬁ  cantly higher 
than the other factors, indicating that surgery time and EPT 
contribute to an increase in IOP. The exact probability of 
this multiple regression equation was conﬁ  rmed by analysis 
of variance (ANOVA; p = 0.0001) (Table 1). In contrast, in 
the diclofenac-treated eyes, ∆IOP was −0.98 ± 1.89 mmHg, 
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Figure 2 Relationship between the ∆IOP and total surgery time in uneventful cataract 
surgery in postoperative betamethasone-treated eyes (A) and diclofenac-treated 
eyes (B) Strong correlation was observed in betamethasone-treated eye (r = 0.499, 
p = 0.002), in contrast little correlation was seen in diclofenac-treated eyes (r = 0.044, 
p = 0.763).
and there was no statistically signiﬁ  cant amount of |b|; 
therefore, a decrease in IOP was not caused by any 
clinical factors (Table 2).
Discussion
This prospective case-control study is unique because each 
patient had one eye treated with betamethasone and the 
other eye treated with diclofenac after cataract surgery. Clinical Ophthalmology 2009:3 99
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eyes also showed a signiﬁ  cant reduction after cataract 
surgery. In contrast, IOP in the betamethasone-treated eyes 
showed signiﬁ  cant increase. Interestingly, within 1 week 
after the surgery, there was no signiﬁ  cant difference in 
IOP between the two groups; however, at 4 and 8 weeks 
postoperatively, IOP in the corticosteroid (betamethasone)-
treated eyes was significantly higher than that in 
NSAID (diclofenac)-treated eyes. It is well known that 
topical corticosteroid-induced IOP elevation is observed 
after 3 weeks of administration.12 Therefore, IOP elevation 
after surgery in the betamethasone-treated eyes is possibly 
“steroid-induced ocular hypertension.”
Although the pathogenesis of steroid-induced ocular 
hypertension still remains unknown, corticosteroid 
affects cytoskeleton, an extracellular matrix in trabecular 
meshwork cells,13 leading to an increase in the outﬂ  ow 
resistance of aqueous humor. However, corticosteroids 
did not always induce ocular hypertension in all cases. 
Previous reports indicated 69% of normal eyes had IOP 
elevations of at least 5 mmHg and were classified as 
steroid responders.14 In this study 18 of 50 eyes showed 
more than 5 mmHg of ∆IOP; in contrast, 23 eyes showed 
less than 0 mmHg of ∆IOP, therefore, those 18 patients 
were considered steroid responders. In these 18 patients, 
∆IOP in the other (diclofenac-treated) eyes showed less 
than 2 mmHg (mean −0.67 ± 2.0 mmHg); therefore, 
diclofenac did not induce ocular hypertension even in 
steroid responders.
The most interesting result in this study is that an 
increase of ∆IOP after uneventful cataract surgery in 
betamethasone- treated eyes was related to surgery time 
and EPT. Longer surgery time and/or EPT usually caused 
more postoperative inﬂ  ammation. Generally, it takes more 
time and/or sonication power to perform cataract surgery in 
complicated cases including those of patients with a hard 
nucleus and/or small pupils. Also, beginning surgeons and 
older patients need more time for surgery. In these cases, 
diclofenac seems to have some advantages compared with 
betamethasone for preventing postoperative increases 
in IOP.
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Figure 3 Relationship between the ∆IOP and EPT in uneventful cataract surgery 
in postoperative betamethasone-treated eyes (A) and diclofenac-treated eyes 
(B) Strong correlation was observed in betamethasone-treated eye (r = 0.535, 
p   0.001), in contrast little correlation was seen in diclofenac-treated eyes (r = −0.080, 
p = 0.584).
In these cases, where patients had both eyes treated, systemic 
conditions can be excluded.
After uneventful cataract surgery in a normal patient, the 
major ﬁ  ndings of this study are as follows. 1) postoperative 
IOP was slightly increased in eyes treated with betamethasone, 
which was dependent upon total surgery time and EPT. 2) In 
contrast, postoperative IOP in eyes treated with diclofenac 
was slightly decreased, and was not affected by surgery 
time or EPT.
According to a recent study, IOP in the nonglauco-
matous eye is reduced following uneventful cataract 
surgery.11 In our study, IOP in the diclofenac-treated Clinical Ophthalmology 2009:3 100
Shimura et al
Table 1 Multiple regression analysis for alteration of ∆IOP in betamethasone-treated eyes
Multiple regression analysis (n = 50) Dependent (y) = ∆IOP (mmHg)
Betamethasone mean SD
+1.74 3.41
Independent (x) Regression factor
mean SD bp
Age (years) 74.8 5.40 0.174 0.174
Gender (0:M, 1:F) 0.58 0.50 −0.095 0.423
Preoperative IOP (mmHg) 14.92 3.21 −0.052 0.661
Preoperative BCVA 0.35 0.22 −0.026 0.823
Total surgery time (min) 8.58 1.28 0.312 0.019
EPT (sec) 52.70 16.60 0.399 0.002
Notes: b: standard partial regression coefﬁ  cient calculated from multiple regression equation, p: level of signiﬁ  cance.
Abbreviations: BCVA, best corrected visual acuity; EPT, effective phaco time; IOP, intraocular pressure; SD, standard deviation.
ANOVA table from multiple regression equation of y = improvement of VA
Cause SS ϕ Ms Fp
Regression 260.84 6 43.47 6.054 0.001
Residual 308.78 43 7.18
Total 596.62 49
Abbreviations: SS, sum of square, ϕ, degree of freedom; Ms, mean of square; F, Ms regression/Ms residual; p, exact possibility.
Table 2 Multiple regression analysis for alteration of ∆IOP in diclofenac-treated eyes
Multiple regression analysis (n = 50) Dependent (y) = ∆IOP (mmHg)
Diclofenac mean SD
−0.98 1.89
Independent (x) Regression factor
mean SD bp
Age (years) 74.8 5.40 0.046 0.755
Gender (0:M, 1:F) 0.58 0.50 0.079 0.581
Preoperative IOP (mmHg) 14.96 3.15 −0.229 0.121
Preoperative BCVA 0.36 0.23 −0.240 0.109
Total surgery time (min) 8.74 1.29 0.128 0.845
EPT (sec) 53.46 14.87 −0.120 0.414
Notes: b: standard partial regression coefﬁ  cient calculated from multiple regression equation, p: level of signiﬁ  cance.
Abbreviations: BCVA, best corrected visual acuity; EPT, effective phaco time; IOP, intraocular pressure; SD, standard deviation.
ANOVA table from multiple regression equation of y = improvement of VA
Cause SS ϕ Ms Fp
Regression 27.13 6 4.52 1.315 0.271
Residual 147.85 43 3.44
Total 174.98 49
Abbreviations: SS, sum of square; ϕ, degree of freedom; Ms, mean of square; F, Ms regression/Ms residual; p, exact possibility.Clinical Ophthalmology 2009:3 101
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